Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer

NCT04997252 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT04997252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04997252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer
Lead sponsor
Zhujiang Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
February 1, 2021
Completion date
December 31, 2024
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk and oligometastatic prostate cancer